←
Khaled Musallam MD PhD34 posts
Khaled Musallam MD PhD avatar✓

Khaled Musallam MD PhD ✓

@drKMusallam

Group Chief Research Officer, Burjeel Holdings (UAE)

◷ Joined February 2022
Wafik S. El-Deiry, MD, PhD, FACP avatar
⟳ Khaled Musallam MD PhD retweeted
Wafik S. El-Deiry, MD, PhD, FACP@weldeiry·2 Mar 2024

Spectacular dinner in honor of the @WIN_Consortium Symposium international faculty at @BurjeelHoldings Chairman Dr. Shamsheer Vayalil’s Villa in Dubai this evening. @drshamsheervp incredible show of hospitality It was a treat to see Nobel Laureate @JimAllisonPhD play a harmonica that’s not the old fashioned one. @PamSharmaMDPhD Worth the 90 minutes back and forth to Dubai from Abu Dhabi. @Dr_R_Kurzrock @SenduraiMani @drdonsdizon @drKMusallam @alshamsi2000 @SilviaRadonc @ChristianRolfo @HatimHusainMD @CancerConnector @VivekSubbiah @IAbuGheidaMD #LegorretaCancerCenter @BrownUCancer @BrownMedicine @BrownUniversity

Post attachmentPost attachment
0:40
0:27
Wafik S. El-Deiry, MD, PhD, FACP avatar
⟳ Khaled Musallam MD PhD retweeted
Wafik S. El-Deiry, MD, PhD, FACP@weldeiry·2 Mar 2024

Terrific two-day international precision oncology event that was successful due to collaboration between the @WIN_Consortium in cancer personalized medicine and @BurjeelHoldings. The founders of the WIN Consortium (the late John Mendelsohn at MD Anderson Cancer Center who was Chair from 2010 until 2018 and the late Thomas Tursz at Gustav Roussy who was Vice Chair in 2010-2012, 2016-2018) had a bold vision for global impact in personalized cancer medicine through innovation and collaboration. winconsortium.org/ This vision holds true today in 2024 where the WIN Consortium is growing both in the US and throughout the world and building upon the remarkable successes over the past 15 years. Our Molecular Tumor Board, next-gen clinical trials and WIN Symposium scientific meetings will drive progress as we grow and implement our vision. We seek like-minded innovators and stakeholders to advance the frontiers of precision oncology to help patients with diversity and equity. True collaboration (and not competition), open-mindedness, humility, and humanistic altruism is what will ultimately realize the impactful vision and advance the field. This can happen faster when academic institutions, big pharma, biotech, professional societies, patient advocacy organizations, governments and funding agencies work together towards a common goal to reduce the burden from cancer. Precision care in oncology has been delivering on its promise and will continue to do so by purposeful implementation. Our predescessors showed feasibility and gave us the opportunity to go to the next level. linkedin.com/posts/burjeel-h… @Dr_R_Kurzrock @drshamsheervp @rschilsky @drKMusallam @alshamsi2000 @JimAllisonPhD @ASCO @SWOG @AmericanCancer @AACR @DrRobWinn @theNCI @NCIDirector @AACR_CEO @AmerCancerCEO @jrgralow @ASCOPres @PamSharmaMDPhD @VivekSubbiah @SenduraiMani @drdonsdizon @CancerConnector @BrainTumorDoc @mpdrc @DrTonyLetai @BrownMedicine @BrownUCancer @kinghorncancer @VHIO @FudanUni @LurieCancer @LeonidasPlatan1 @RoyJensenMD @slibutti

3:48
Wafik S. El-Deiry, MD, PhD, FACP avatar
⟳ Khaled Musallam MD PhD retweeted
Wafik S. El-Deiry, MD, PhD, FACP@weldeiry·4 Mar 2024

Dr. Jacob Scott @CancerConnector @caseccc makes case for the radiotherapy of tomorrow that is tailored to each patient through a genomic-adjusted radiation dose (GARD) @WIN_Consortium Symposium in Abu Dhabi @IAbuGheidaMD @drKMusallam @alshamsi2000 @Dr_R_Kurzrock @VivekSubbiah @SenduraiMani @BurjeelHoldings @SilviaRadonc @BrownUCancer @drdonsdizon @bcarneiro7 @BrownMedicine @BrownUniversity #LegorretaCancerCenter

Post attachmentPost attachmentPost attachmentPost attachment